Keith L. March, MD, PhD, FACC, has dedicated his career to bringing new medical approaches to patients. His publications include more than 190 manuscripts. He was editor of the first book dedicated to cardiovascular gene transfer. Dr. March’s research has resulted in more than 60 worldwide (20+ U.S.) patents, with others pending. He invented the Closer, a widely-utilized patented suture-mediated closure device, used to close the puncture wound in an artery following heart catheterization. This device allows a patient to “walk off the table” after a catheterization without requiring prolonged bedrest. In 1999, Abbott Vascular acquired this technology; and the Closer approach has been used worldwide to treat more than 11,000,000 patients. He has served as scientific advisor to numerous pharmaceutical, biotechnology and medical device companies. His laboratory was the first in the world to establish that the paracrine factors secreted by stem cells, known as secretome, were powerful off-the-shelf therapeutics for a range of critical medical needs. Building on this discovery, he co-founded Theratome Bio, with a patented platform directed to ameliorating ischemic and inflammatory disease.

Dr. March is recognized as a leading expert in the field of adult stem cell research, particularly adipose stem cells. From 2008-2012, he was Chair of the National Institutes of Health Data and Safety Monitoring Board that oversees cell and gene therapy trials in the areas of heart, lung, and blood diseases. From 2012-2019, he was a lead investigator in the Cardiovascular Cell Therapy Research Network (CCTRN), involving 7 centers in the USA conducting NIH-sponsored cell therapy clinical trials. He has spearheaded FDA authorization of numerous trials employing fat-derived or umbilical cord lining-derived stem cells, obtaining more than 30 FDA IND authorizations between 2021-2025. He joined Restem as Chief Medical Officer in 2024.

Dr. March has also served as the President (2007) of the International Federation of Adipose Therapeutics and Science (IFATS), and on the IFATS Board as well as other committees and boards in the field. He provides consultative assistance in obtaining FDA approval for cell-based therapies. During the pandemic, he developed a complementary passion for advancing a disruptive digital health model using a high-touch patient-centered approach to improve wellness. This vision is being implemented by Kindly Reminders, LLC, harnessing the power of empathy to develop patient engagement at a level far surpassing norms in the digital health industry. In 2024, TeleBP was founded to expand Kindly Reminders' reach, bringing its innovative and compassionate approach to even more individuals in need of effective blood pressure management.